Goldman Sachs Group, Inc. (The) Reiterates Buy Rating for GlaxoSmithKline plc (LON:GSK)

GlaxoSmithKline plc (LON:GSK)‘s stock had its “buy” rating reissued by Goldman Sachs Group, Inc. (The) in a research report issued on Tuesday, October 17th. They currently have a GBX 1,900 ($24.99) price target on the stock. Goldman Sachs Group, Inc. (The)’s target price suggests a potential upside of 39.65% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on the company. Barclays PLC reaffirmed an “equal weight” rating and issued a GBX 1,550 ($20.39) target price on shares of GlaxoSmithKline plc in a report on Monday, July 3rd. Jefferies Group LLC reiterated a “buy” rating and issued a GBX 1,900 ($24.99) price target on shares of GlaxoSmithKline plc in a research note on Thursday, July 13th. Deutsche Bank AG reaffirmed a “hold” rating and set a GBX 1,610 ($21.18) target price on shares of GlaxoSmithKline plc in a research report on Wednesday, October 11th. Liberum Capital reaffirmed a “buy” rating and set a GBX 1,900 ($24.99) target price on shares of GlaxoSmithKline plc in a research report on Wednesday, August 30th. Finally, J P Morgan Chase & Co lowered their price objective on GlaxoSmithKline plc from GBX 1,750 ($23.02) to GBX 1,570 ($20.65) and set a “neutral” rating for the company in a research report on Wednesday, September 13th. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating and six have assigned a buy rating to the company’s stock. GlaxoSmithKline plc presently has a consensus rating of “Hold” and an average price target of GBX 1,612.25 ($21.21).

GlaxoSmithKline plc (LON:GSK) traded down GBX 0.50 ($0.01) during trading hours on Tuesday, reaching GBX 1,360.50 ($17.89). The company’s stock had a trading volume of 6,536,227 shares.

GlaxoSmithKline plc (LON:GSK) last issued its quarterly earnings results on Wednesday, October 25th. The company reported GBX 32.50 ($0.43) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of GBX 31.80 ($0.42) by GBX 0.70 ($0.01). The business had revenue of GBX 784.30 billion for the quarter. GlaxoSmithKline plc had a negative return on equity of 57.19% and a negative net margin of 1.17%.

TRADEMARK VIOLATION WARNING: “Goldman Sachs Group, Inc. (The) Reiterates Buy Rating for GlaxoSmithKline plc (LON:GSK)” was originally posted by BBNS and is the property of of BBNS. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://baseballnewssource.com/markets/glaxosmithkline-plcs-gsk-buy-rating-reaffirmed-at-goldman-sachs-group-inc/1721030.html.

In other GlaxoSmithKline plc news, insider Simon Dingemans purchased 1,076 shares of the firm’s stock in a transaction on Thursday, October 12th. The shares were acquired at an average cost of GBX 1,527 ($20.08) per share, for a total transaction of £16,430.52 ($21,610.57). Also, insider Urs Rohner purchased 473 shares of the firm’s stock in a transaction on Wednesday, October 25th. The stock was acquired at an average price of GBX 1,518 ($19.97) per share, for a total transaction of £7,180.14 ($9,443.82). In the last quarter, insiders have bought 1,574 shares of company stock worth $2,398,888.

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with our FREE daily email newsletter.

 


Latest News

Toronto Blue Jays Launch Internal Investigation on PED Use
Toronto Blue Jays Launch Internal Investigation on PED Use
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player


Leave a Reply

 
© 2006-2017 BBNS.